About this trial
evaluate the efficacy and safety of "Selinexor+pegaspargase+dexamethasone" in early stage NK/ T-cell lymphoma
Eligibility criteria
Qualifiers
Age 18-70 years old, ECOG score 0-2; (including those aged 18 and 70);
Pre-survival time > 6 months;
The pathological tissue was confirmed as NK/T cell lymphoma (the pathological report of the first three months of enrollment could be accepted) (Note: If there is any doubt about the pathological diagnosis, domestic third-party consultation could be organized);
Clinical stage Ⅰ to Ⅱ (CA stage) with at least one measurable lesion;
Disqualifiers
Refuse to collect blood samples;
Previous allergy to any of the drugs in the program;
Pregnant and lactating women;
Major diseases that the investigator believes can cause interference with the test;
Trial design
Treatments tested in this trial
- Selinexor+pegaspargase+dexamethasone
Treatment groups
Sponsors and collaborators
Mingzhi Zhang
Lead sponsor
Zhengzhou University
Sponsor institution